ABSTRACT:We report the investigation of sulfonamidederived Ca v 2.2 inhibitors to address drug-metabolism liabilities with this lead class of analgesics. Modification of the benzamide substituent provided improvements in both potency and selectivity. However, we discovered that formation of the persistent 3-(trifluoromethyl)-benzenesulfonamide metabolite was an endemic problem in the sulfonamide series and that the replacement of the center aminopiperidine scaffold failed to prevent this metabolic pathway. This issue was eventually addressed by application of a bioisostere strategy. The new gem-dimethyl sulfone series retained Ca v 2.2 potency without the liability of the circulating sulfonamide metabolite. KEYWORDS: Ca v 2.2, N-type calcium channel, pain, sulfonamide, bioisostere, sulfone N -Type calcium channels (Ca v 2.2) are expressed in the presynaptic termini of primary afferent nociceptors in the spinal cord and are key components of the pain transmission pathway. We have previously reported the discovery of a series of aminopiperidine sulfonamide state-dependent Ca v 2.2 channel inhibitors with potential utility for the treatment of chronic pain. Members of this class are orally bioavailable and efficacious in preclinical pain models. 1 In particular, 1 ( Figure 1) is selective for inhibition of the Ca v 2.2 channel over the cardiovascular ion channels hERG and Ca v 1.2, with a decent preclinical PK and biodistribution profile. The compound exhibits dose-dependent efficacy in preclinical models of inflammatory hyperalgesia and neuropathic allodynia, but it has no efficacy in Ca v 2.2 gene-deleted mice. The compound is also devoid of ancillary preclinical cardiovascular or CNS pharmacology. While 1 may be used as a preclinical tool to evaluate state-dependent inhibition of Ca v 2.2 channels, it has several drug metabolism related issues that confound further development of the compound. These include moderate CYP3A4 inhibition (IC 50 = 5.1 μM), PXR activation (EC 50 = 0.43 μM), and the formation of the persistent circulating metabolite 2. The sulfonamide metabolite 2 exhibited preclinical antinociceptive activity in its own right, although it was devoid of significant Ca v 2.2 activity. In order to further improve this lead class of Ca v 2.2 inhibitors and address the drug metabolism issues associated with this series, SAR optimization studies were carried out on the amide substituent and the aminopiperidine core, and a bioisostere replacement strategy was pursued for the sulfonamide moiety.The first substituent to be investigated for further optimization was the benzoic amide moiety (Table 1). The synthesis of piperidine sulfonamide compounds listed in Table 1 was straightforward as described previously. 1 This synthetic route allowed rapid SAR studies modifying substitutions on the benzamide phenyl ring. In some instances, the desired benzoic acid partner had to be synthesized. For example, the intermediate 4-(methylsulfonyl)-2-trifluoromethoxy-benzoic